RN2 Technologies Co., Ltd. (KOSDAQ:148250)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,860.00
-490.00 (-7.72%)
At close: Aug 7, 2025, 3:30 PM KST
-7.72%
Market Cap55.36B
Revenue (ttm)14.73B
Net Income (ttm)-2.76B
Shares Out9.45M
EPS (ttm)-377.85
PE Ration/a
Forward PEn/a
Dividend30.00 (0.47%)
Ex-Dividend DateDec 27, 2024
Volume158,524
Average Volume51,366
Open6,350.00
Previous Close6,350.00
Day's Range5,300.00 - 6,550.00
52-Week Range3,330.00 - 9,470.00
Beta0.50
RSI27.97
Earnings DateAug 12, 2025

About Verve Therapeutics

RN2 Technologies Co., Ltd. engages in the multi-layer components, multi-layer ceramic PCB, and LTCC power material business. It offers 90-degrees hybrid, directional, asymmetric, and broadband couplers; Doherty combiners; terminations; delay lines; dividers; attenuators; quadrifilars; and MCP foundry service with LTCC, alumina, AlN, Al2O3, and ZTA substrates. The company was founded in 2002 and is headquartered in Hwaseong-si, South Korea. [Read more]

Industry Electronic Components And Accessories
Founded 2002
Employees 104
Stock Exchange KOSDAQ
Ticker Symbol 148250
Full Company Profile

Financial Performance

In 2024, RN2 Technologies's revenue was 14.30 billion, a decrease of -2.61% compared to the previous year's 14.69 billion. Losses were -1.72 billion, -53.37% less than in 2023.

Financial Statements

News

There is no news available yet.